Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 2.95 -1.67% -0.05
ACRX closed down 1.67 percent on Friday, August 18, 2017, on 37 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ACRX trend table...

Date Alert Name Type % Chg
Aug 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Aug 17 Narrow Range Bar Range Contraction -1.67%
Aug 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.67%
Aug 16 NR7 Range Contraction -1.67%
Aug 16 Narrow Range Bar Range Contraction -1.67%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.08
52 Week Low 1.95
Average Volume 1,259,070
200-Day Moving Average 2.808
50-Day Moving Average 2.7115
20-Day Moving Average 3.195
10-Day Moving Average 2.9725
Average True Range 0.2352
ADX 17.01
+DI 18.73
-DI: 17.22
Chandelier Exit (Long, 3 ATRs) 3.3444
Chandelier Exit (Short, 3 ATRs) 3.4056
Upper Bollinger Band 3.8983
Lower Bollinger Band 2.4917
Percent B (%b) 0.33
Bandwidth 0.44025
MACD Line 0.0395
MACD Signal Line 0.0866
MACD Histogram -0.0471